Advertisement
Advertisement

RLMD

RLMD logo

Relmada Therapeutics Inc

0.3565
USD
-0.0052
-1.44%
Dec 18, 15:52 UTC -5
Closed
...

Relmada Therapeutics Inc Profile

About

Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics Inc. is based in New York.

Info & Links

CEO

Sergio Traversa

Headquarters

2222 PONCE DE LEON BLVD. 3RD FLOOR
CORAL GABLES, FL 33134, UNITED STATES

Industry

Pharmaceuticals Major

Sector

Health Technology

Website

www.relmada.com

Auditor

Marcum LLP

Share holders

129

Employees

20

Relmada Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

10.76M

Enterprise Value

9.27M

Enterprise Value/EBITDA(ttm)

-0.10

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

0.23

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-129.80%

Return on Invested Capital(ttm)

-134.29%

Return on Assets(ttm)

-112.06%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-91.64M

Net Income Available to Common(ttm)

-86.49M

Diluted EPS(ttm)

-2.87

Share Statistics

Beta (5Y Monthly)

0.35

52-Week Change

-85.80%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

30.17M

Dividend Yield

0.00%

Float4

24.74M

% Held by Insiders

18.00%

% Held by Institutions

45.24%

Balance Sheet

Total Cash(mrq)

54.12M

Total Cash Per Share(mrq)

1.79

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

6.89%

Quick Ratio(mrq)

6.89%

Book Value Per Share(mrq)

1.58

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.42

Free Cash Flow(ytd)

-42.96M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement